Latest Regulatory News

Macquarie Group Limited reported a 3% increase in half-year profit to $1.655 billion, driven by growth across its asset management, banking, commodities, and capital markets divisions. The group maintains robust capital and liquidity positions despite margin pressures and regulatory challenges.

Macquarie Group reported a solid half-year profit increase despite a sequential dip, boosted by strong asset management and capital markets performance. The group also extended its share buyback and declared a steady interim dividend.

Macquarie Group Limited reported a 3% increase in profit for the half year ended 30 September 2025, driven by strong performances in asset management and capital advisory, while declaring a 35% franked interim dividend of $2.80 per share.

Finexia Financial Group has formally ended preliminary discussions with Salter Brothers regarding a potential reverse listing and is seeking immediate reinstatement of its ASX securities.

VGI Partners Global Investments Limited has announced an on-market buy-back of its ordinary shares, set to begin in late November 2025 and run for a full year. The buy-back offers a flexible approach without fixed volume limits or a set price, signaling a strategic capital management move.

Proteomics International secures half a million dollars from the Western Australian Government to accelerate commercialisation of PromarkerEndo, a groundbreaking blood test for early endometriosis diagnosis.

ALS Limited has responded to an ASX inquiry regarding the delayed lodgement of key disclosure documents related to performance rights granted to director Malcolm Deane, attributing the delay to human error and outlining steps to reinforce compliance.

James Hardie Industries faces intense scrutiny from the ASX after its share price dropped sharply and trading volumes spiked, prompting urgent questions about undisclosed information.

Arafura Rare Earths Limited has announced a Share Purchase Plan (SPP) targeting $50 million to support its Nolans Project, subject to shareholder approval. The offer allows eligible shareholders to subscribe for shares at a discounted price, with potential oversubscriptions up to $20 million.

Aeris Resources has launched a Share Purchase Plan offering eligible shareholders in Australia and New Zealand the chance to buy shares at a discounted price, aiming to raise up to $10 million for working capital.

Chimeric Therapeutics has responded to ASX inquiries regarding the disclosure timing and materiality of new clinical data from its ADVENT-AML trial, emphasizing compliance with continuous disclosure rules and the careful verification of promising patient responses.

Seven West Media reports a 6% EBITDA rise in H2 FY25 driven by TV and digital growth, while announcing a transformative merger with Southern Cross Media.